PMID- 36070745
OWN - NLM
STAT- MEDLINE
DCOM- 20220909
LR  - 20221018
IS  - 1439-4286 (Electronic)
IS  - 0018-5043 (Linking)
VI  - 54
IP  - 9
DP  - 2022 Sep
TI  - Homocysteine and the Mortality of Critically Ill Patients: A Meta-Analysis.
PG  - 593-603
LID - 10.1055/a-1897-5992 [doi]
AB  - Prevalence of hyperhomocysteinemia (HHcy) is high in critically ill patients. 
      However, the association between serum homocysteine level and outcomes of the 
      critically ill patients remains unknown. We performed a meta-analysis of cohort 
      studies to comprehensively evaluate the above association. Relevant cohort 
      studies were identified by search of electronic databases including PubMed, 
      Embase, Web of Science, Wanfang, and CNKI from the inception of the databases to 
      February 5, 2022. A randomized-effect model incorporating the possible 
      between-study heterogeneity was used to pool the results. Overall, 16 cohorts 
      with 1663 critically ill patients who were admitted to the intensive care unit 
      (ICU) were involved in the meta-analysis. Pooled results showed that compared to 
      non-survivors of the critical illnesses, survivors had significantly lower serum 
      level of Hcy at ICU admission [mean difference (MD): -3.42 mumol/l, 95% confidence 
      interval (CI): -5.89 to 0.94, p=0.007; I2=86%]. Subgroup analysis showed that the 
      difference of Hcy between survivors and non-survivors was significant in Asian 
      patients (MD: -8.17 mumol/l, p<0.001), but not in non-Asians (MD: 0.30 mumol/l, 
      p=0.62; p for subgroup difference<0.001). Moreover, meta-analysis with seven 
      cohorts, all including Chinese patients, showed that HHcy at ICU admission was 
      independently associated with a higher risk of all-cause mortality in critically 
      ill patients (odds ratio: 2.99, 95% CI: 2.26 to 3.97, p<0.001; I2=69%). A higher 
      serum level of Hcy at ICU admission may be associated with an increased risk of 
      all-cause mortality in critically ill patients, particularly in the Chinese 
      population.
CI  - Thieme. All rights reserved.
FAU - Yuan, Fawei
AU  - Yuan F
AD  - Department of Intensive Care Unit, Huangshi Central Hospital, Affiliated Hospital 
      of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, China.
AD  - Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi, 
      Hubei, China.
FAU - Zheng, Kun
AU  - Zheng K
AD  - Department of Intensive Care Unit, Huangshi Central Hospital, Affiliated Hospital 
      of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, China.
AD  - Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi, 
      Hubei, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220907
PL  - Germany
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Cohort Studies
MH  - Critical Illness/*mortality
MH  - Homocysteine/blood
MH  - Humans
MH  - Hyperhomocysteinemia/epidemiology/*mortality
MH  - Intensive Care Units
COIS- The authors declare that they have no conflict of interest.
EDAT- 2022/09/08 06:00
MHDA- 2022/09/11 06:00
CRDT- 2022/09/07 18:42
PHST- 2022/09/07 18:42 [entrez]
PHST- 2022/09/08 06:00 [pubmed]
PHST- 2022/09/11 06:00 [medline]
AID - 10.1055/a-1897-5992 [doi]
PST - ppublish
SO  - Horm Metab Res. 2022 Sep;54(9):593-603. doi: 10.1055/a-1897-5992. Epub 2022 Sep 
      7.